The University of Pittsburgh Cancer Institute (UPCI) was formed in 1985, and over the twenty-three years since then has amassed a cadre of more than 400 basic and clinical investigators with broad basic and clinical expertise that relates to the ECOG in relation to many of its disease and modality committees. The Eastern Cooperative Oncology Group (ECOG) is the major extramural focus of multi-modal clinical investigations in adult solid tumors of the UPCI. UPCI is based in the hospitals of the University of Pittsburgh Medical Center (UPMC), a health system consisting of UPMC Presbyterian (PUH), UPMC Montefiore (MUH), the Eye and Ear Hospital and Institute, UPMC Shadyside Hospital, Western Psychiatric Hospital and Clinic, Falk Clinic, and the Magee Women's Hospital. In 2002, The UPMC Cancer Centers were formed, including a broad array of more than 45 locations that serve as the base of operations for full-time and clinical faculty of the UPCI who are active in ECOG within Pittsburgh and across the region. These include UPMC Shadyside, UPMC Bedford Memorial, UPMC Braddock, UPMC Horizon-Greenville and Shenango Valley, UPMC Lee Regional, UPMC McKeesport, UPMC Northwest Franklin and Oil City, UPMC Passavant, Cranberry, UPMC Southside, Children's Hospital of Pittsburgh, UPMC St. Margaret's, UPMC Mercy, Magee Women's Hospital, Beaver Valley, Latrobe Area Hospital, Heritage Valley Health System, Westmorland Hospital, Jameson Health System, Jefferson Regional Medical Center, Memorial Medical Center, The Washington Hospital, Uniontown Hospital and Frick Hospital as well as the UPMC Rehabilitation Hospital. These facilities provide for a cachement area that extends across Western Pennsylvania from W. Virginia to Ohio and New York State. The Oakland Veterans Administration Medical Center is a consortium member of ECOG, affording access to ECOG studies for patients of the VA system. UPMC relocated inpatient UPCI clinical facilities to MUH in 1993, and to the Hillman Cancer Center - UPMC Shadyside Medical Center in 2003, with full service inpatient Medical Oncology, Surgical Oncology, and Hematology/BMT as well as a satellite Clinical Translational Science Institute (CTSI) in the outpatient Hillman Cancer Center Ambulatory Care Facility. A range of ECOG studies with laboratory components are being conducted on this CTSI, providing support for protocol therapy of patients on ECOG trials beyond what would be possible with third party payer coverage. The basic cancer research space of UPCI has been consolidated in the Hillman Cancer Center Research Pavilion that was completed in 2002, offering state-of-the-art research laboratories contiguous with the outpatient and inpatient facilities. Those that relate directly to ECOG include the Clinical Immunologic Monitoring Laboratory (IMCPL) which serves as the Core Immunological Monitoring Laboratory for ECOG, the Serum and Tissue Bank, and Flow Cytometry FACS/Hybridoma facilities. Separately located on the campus of the UPMC are Crystallography, Peptide Synthesis, and Oligonucleotide Synthesis facilities. The Clinical Research Services are now located in the Hillman Cancer Center Cooper Ambulatory Pavilion, while the Biostatistical Office is located at the Sterling Building several blocks closer to the Oakland Campus. UPCI and UPMC have developed as matrix organizations in which the traditional academic departments and divisions of Hematology/Oncology, Surgical Oncology, and Radiation Oncology are configured along disease-oriented lines to facilitate the growth and development of interdisciplinary disease-oriented and modality programs.

Public Health Relevance

The Eastern Cooperative Oncology Group (ECOG) is the major extramural focus of multi-modal clinical Investigations In adult solid tumors of the UPCI. UPCI is based in the hospitals of the University of Pittsburgh Medical Center (UPMC).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Bakhru, Pearl; Zhu, Meng-Lei; Wang, Hsing-Hui et al. (2017) Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight 2:
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41
Schneider, Bryan P; Li, Lang; Radovich, Milan et al. (2015) Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21:5082-5091

Showing the most recent 10 out of 59 publications